MX2021012782A - El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion. - Google Patents
El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion.Info
- Publication number
- MX2021012782A MX2021012782A MX2021012782A MX2021012782A MX2021012782A MX 2021012782 A MX2021012782 A MX 2021012782A MX 2021012782 A MX2021012782 A MX 2021012782A MX 2021012782 A MX2021012782 A MX 2021012782A MX 2021012782 A MX2021012782 A MX 2021012782A
- Authority
- MX
- Mexico
- Prior art keywords
- molecular weight
- low molecular
- high concentration
- pvp
- reduce viscosity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837647P | 2019-04-23 | 2019-04-23 | |
| PCT/US2020/029328 WO2020219550A1 (en) | 2019-04-23 | 2020-04-22 | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012782A true MX2021012782A (es) | 2021-11-25 |
Family
ID=70614677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012782A MX2021012782A (es) | 2019-04-23 | 2020-04-22 | El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12599669B2 (enExample) |
| EP (1) | EP3958840A1 (enExample) |
| JP (1) | JP7739182B2 (enExample) |
| CN (1) | CN113660927A (enExample) |
| AU (1) | AU2020263318B2 (enExample) |
| CA (1) | CA3141857A1 (enExample) |
| MX (1) | MX2021012782A (enExample) |
| WO (1) | WO2020219550A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| CN113660927A (zh) | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
| CA3214867A1 (en) * | 2021-04-09 | 2022-10-13 | Courtney O'DELL | Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961955A (en) | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US6992066B2 (en) | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| US20080026068A1 (en) | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
| JP4679822B2 (ja) | 2002-03-13 | 2011-05-11 | ノバルティス アーゲー | 医薬微粒子 |
| KR20110097772A (ko) | 2008-11-17 | 2011-08-31 | 제넨테크, 인크. | 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제 |
| AU2009339292B2 (en) | 2008-12-10 | 2016-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| WO2016014408A1 (en) | 2014-07-21 | 2016-01-28 | Board Of Regents, The University Of Texas System | Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same |
| ES2964713T3 (es) * | 2014-10-23 | 2024-04-09 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| CN106511997A (zh) | 2015-09-15 | 2017-03-22 | 上海抗体药物国家工程研究中心有限公司 | 一种稳定的蛋白制剂 |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US12103979B2 (en) * | 2017-04-28 | 2024-10-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
| MA48461A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| CN113660927A (zh) | 2019-04-23 | 2021-11-16 | 安进公司 | 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 |
-
2020
- 2020-04-22 CN CN202080026162.6A patent/CN113660927A/zh active Pending
- 2020-04-22 US US17/605,512 patent/US12599669B2/en active Active
- 2020-04-22 JP JP2021562350A patent/JP7739182B2/ja active Active
- 2020-04-22 WO PCT/US2020/029328 patent/WO2020219550A1/en not_active Ceased
- 2020-04-22 CA CA3141857A patent/CA3141857A1/en active Pending
- 2020-04-22 MX MX2021012782A patent/MX2021012782A/es unknown
- 2020-04-22 AU AU2020263318A patent/AU2020263318B2/en active Active
- 2020-04-22 EP EP20724707.3A patent/EP3958840A1/en active Pending
-
2026
- 2026-03-10 US US19/562,671 patent/US20260199478A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220226477A1 (en) | 2022-07-21 |
| EP3958840A1 (en) | 2022-03-02 |
| WO2020219550A1 (en) | 2020-10-29 |
| CN113660927A (zh) | 2021-11-16 |
| CA3141857A1 (en) | 2020-10-29 |
| JP7739182B2 (ja) | 2025-09-16 |
| JP2022529996A (ja) | 2022-06-27 |
| US12599669B2 (en) | 2026-04-14 |
| US20260199478A1 (en) | 2026-07-16 |
| AU2020263318A1 (en) | 2021-10-21 |
| AU2020263318B2 (en) | 2025-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| ES2710126T3 (es) | Extracto de saliva completa de sanguijuela | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| CL2023003327A1 (es) | Inhibidores de la interaccion de menina-mll | |
| CO2017008862A2 (es) | Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| PE20241305A1 (es) | Analogos de amilina | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| CR8932A (es) | Composicion de anticuerpo her2 | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| AR040075A2 (es) | 1h-pirimido[4,5-d]pirimidin-2-onas y sales, composiciones farmaceuticas y uso para la fabricacion de un medicamento | |
| MX2013003419A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. | |
| CO6531469A2 (es) | Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| CL2024003428A1 (es) | "formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas. | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| CN110740745B (zh) | 含有谷胱甘肽二硫化物和谷胱甘肽二硫化物s-氧化物的药物组合物 | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| CY1113948T1 (el) | Θεραπευτικα δραστικα αλφα-msh αναλογα | |
| CU24193B1 (es) | El polietileno glicol conjugado de interferon alfa, representado por un isómero posicional | |
| AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. |